Advertisement
Advertisement
U.S. markets close in 3 hours 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Calithera Biosciences, Inc. (CALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7457-0.0523 (-6.55%)
As of 12:03PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.7980
Open0.7900
Bid0.7464 x 1000
Ask0.7522 x 1400
Day's Range0.7411 - 0.7973
52 Week Range0.7411 - 6.1850
Volume425,422
Avg. Volume1,694,591
Market Cap55.872M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-0.9410
Earnings DateNov 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CALA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Calithera Biosciences, Inc.
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • Zacks

    Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?

    Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    Good morning, investor! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, IPOs, acquisition news, and more have stocks moving during this morning’s pre-market trading. Let’s dive into those pre-market stock movers below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-Market Stock Movers: 10 Top Gainers Sono Group (NASDAQ:SEV) stock is soaring more than 27% after

  • GlobeNewswire

    Calithera to Present at the 2021 Jefferies London Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. Eastern Time, and can be accessed through the Investors

Advertisement
Advertisement